Neurogene Inc. - Common Stock (NQ:NGNE)

27.55 -1.27 (-4.41%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Neurogene Inc. - Common Stock

< Previous 1 2 Next >

Which stocks are moving on Friday? ↗

February 27, 2026

Via Chartmill

Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗

February 27, 2026

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

February 26, 2026

Via Chartmill

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 09, 2025

Via Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be...

Via Benzinga

Topics ETFs Stocks

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Via Benzinga

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗

August 11, 2025

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Via Benzinga

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 11, 2025

Via Benzinga

Which stocks are moving on Tuesday? ↗

July 01, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 01, 2025

Via Benzinga

Which stocks are experiencing notable movement on Tuesday? ↗

July 01, 2025

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday ↗

May 16, 2025

Via Benzinga

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 14, 2025

Via Benzinga

Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

May 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 31, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 26, 2024

Via Benzinga

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

November 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 18, 2024

Via Benzinga

Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November ↗

November 18, 2024

Via Benzinga

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 18, 2024

Via Benzinga

Dow Falls 100 Points; Brady Posts Upbeat Results ↗

November 18, 2024

Via Benzinga

Topics Stocks

Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug ↗

November 18, 2024

The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect.

Via Investor's Business Daily

Earnings Scheduled For November 15, 2024 ↗

November 15, 2024

Via Benzinga

Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

November 14, 2024

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 12, 2024

Via Benzinga

Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings ↗

November 12, 2024

Via Benzinga

Topics Stocks

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial ↗

November 12, 2024

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing improved safety and efficacy.

Via Benzinga

Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect ↗

November 12, 2024

Neurogene tested its gene therapy in female patients with Rett syndrome.

Via Investor's Business Daily

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.